0000899243-21-035843.txt : 20210914
0000899243-21-035843.hdr.sgml : 20210914
20210914173029
ACCESSION NUMBER: 0000899243-21-035843
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210910
FILED AS OF DATE: 20210914
DATE AS OF CHANGE: 20210914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KLASKIN CHRISTINE M
CENTRAL INDEX KEY: 0001288123
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 211253300
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-10
0
0001098972
AGENUS INC
AGEN
0001288123
KLASKIN CHRISTINE M
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
0
1
0
0
PFO & PAO
Common Stock
2021-09-10
4
M
0
16563
3.36
A
104176
D
Common Stock
2021-09-10
4
S
0
11120
6.50
D
93056
D
Stock Option, right to buy
3.36
2021-09-10
4
M
0
16563
0.00
D
2011-12-14
2021-09-14
Common Stock
16563
0
D
The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.
The number of shares beneficially owned by the reporting person does not reflect 998 shares that were incorrectly reported on prior Form 4s.
Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.47 to $6.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Christine M. Klaskin
2021-09-14